This invention provides Compounds I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. Compound I is ##STR00001## wherein: Q is selected from the group consisting of: ##STR00002## m is 1 or 2; --W-- is ##STR00003## A is selected from the group consisting of C.sub.1-6alkoxy, aryl and heteroaryl; in which said aryl is phenyl or napthyl; said heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, benzoimidazolyl and benzothiazolyl; and said aryl or heteroaryl is optionally substituted with one or two of the same or different members selected from the group consisting of amino, nitro, cyano, hydroxy, C.sub.1-6alkoxy, --C(O)NH.sub.2; and C.sub.1-6alkyl, --NHC(O)CH.sub.3, halogen and trifluoromethyl.

 
Web www.patentalert.com

< Isoxazole compositions useful as inhibitors of ERK

> Chemokine receptor binding heterocyclic compounds with enhanced efficacy

~ 00424